EVIDENCE meta-analysis

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

May, 2025

EVIDENCE meta-analysis

May 24, 2024, 01:21 | Insight

Recent FDA Committee Vote Could Speed Multiple Myeloma Drug Approval

Sylvester-led analysis on minimal residual disease as clinical endpoint guided committee decision A U.S. Food…

Apr 25, 2024, 21:33 | Blog

C. Ola Landgren: It was an honor to present the EVIDENCE meta-analysis at ODAC

C. Ola Landgren, Chief of the Division of Myeloma at University of Miami and Leader…

Apr 14, 2024, 12:56 | Insight

Carl Ola Landgren: Can MRD serve as early endpoint for accelerated approval in myeloma, to facilitate patient’s access to new drugs

Carl Ola Landgren, Professor of Medicine, Chief of Myeloma Division at University of Miami, shared…

Apr 13, 2024, 03:43 | Blog

FDA ODAC voted 12-0. Historic victory in multiple myeloma

On April 12, 2024, FDA ODAC voted 12-0 in favor of using minimal residual disease…

All: 4 Posts: 1 - 100

'

Francesco Acerbi and Testicular Cancer: The Defender's Fight and Triumphant Return to Football

'

Yvonne Award for Breakthrough Research 2024 Recipient to Time100 Health List

'

Dato' Dr Saunthari Somasundaram: I’m deeply honored to be elected as the next President-Elect of the NCD Alliance

'

Does Plastic Cause Cancer? Myths and Facts

'

TOPGEAR trial at ESTRO 2025: Preoperative Chemoradiotherapy for Resectable Gastric Cancer

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023